BAI – BenevolentAI SA


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 6

Low: 3.43

High: 8.86

Total Analysts: 3

Company Profile

BenevolentAI SA is a United Kingdom-based clinical-stage Artificial Intelligence (AI) drug discovery company. The Company through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. It has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.

We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan